Josh Schimmer
Stock Analyst at Evercore ISI Group
(2.33)
# 2,422
Out of 4,829 analysts
128
Total ratings
38.05%
Success rate
-1.13%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $151.46 | +84.87% | 3 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $23.74 | +215.92% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $10.45 | +378.47% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $2.08 | +861.54% | 2 | Mar 25, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $34.17 | +178.02% | 10 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $132.18 | +62.66% | 5 | Feb 20, 2025 | |
| SEPN Septerna | Reiterates: Overweight | $50 | $6.69 | +647.38% | 2 | Feb 11, 2025 | |
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $0.62 | +706.45% | 4 | Dec 20, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $200 | $25.56 | +682.47% | 6 | Dec 11, 2024 | |
| TRML Tourmaline Bio | Reiterates: Overweight | $25 | $15.10 | +65.56% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.21 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $6.99 | +829.90% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $13.44 | +123.21% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.08 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.17 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $30.68 | +193.35% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.52 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $65.08 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.03 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.98 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.60 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $57.55 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.29 | +5,019.45% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $27.87 | +90.17% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $35.02 | +85.61% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $44.27 | +35.53% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.19 | +4,101.68% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $1.24 | +303.23% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.38 | +697.10% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $115.71 | +12.35% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $527.78 | +44.00% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $11.31 | +32.68% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $7.54 | +629.44% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.68 | +1,685.71% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.44 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.52 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $299.69 | -16.58% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3,500 → $4,600 | $3.50 | +131,328.57% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $58.98 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $32.30 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.17 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $14.37 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $12.79 | +72.01% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.98 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.86 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $184.60 | -48.54% | 1 | Aug 17, 2017 |
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $151.46
Upside: +84.87%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $23.74
Upside: +215.92%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $10.45
Upside: +378.47%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $2.08
Upside: +861.54%
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $34.17
Upside: +178.02%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $132.18
Upside: +62.66%
Septerna
Feb 11, 2025
Reiterates: Overweight
Price Target: $50
Current: $6.69
Upside: +647.38%
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $0.62
Upside: +706.45%
Janux Therapeutics
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $25.56
Upside: +682.47%
Tourmaline Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $15.10
Upside: +65.56%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.21
Upside: -
Nov 19, 2024
Reiterates: Overweight
Price Target: $65
Current: $6.99
Upside: +829.90%
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $13.44
Upside: +123.21%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.08
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.17
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $30.68
Upside: +193.35%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $65.08
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.03
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.98
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.60
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $57.55
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.29
Upside: +5,019.45%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $27.87
Upside: +90.17%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $35.02
Upside: +85.61%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $44.27
Upside: +35.53%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.19
Upside: +4,101.68%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $1.24
Upside: +303.23%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.38
Upside: +697.10%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $115.71
Upside: +12.35%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $527.78
Upside: +44.00%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $11.31
Upside: +32.68%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $7.54
Upside: +629.44%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.68
Upside: +1,685.71%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.44
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $7.52
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $299.69
Upside: -16.58%
Jun 19, 2018
Upgrades: Outperform
Price Target: $3,500 → $4,600
Current: $3.50
Upside: +131,328.57%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $58.98
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $32.30
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.17
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $14.37
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $12.79
Upside: +72.01%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $8.98
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $58.86
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $184.60
Upside: -48.54%